Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1

Background Neutralization of interferon (IFN)-γ abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II but can be induced to do so by IFN-γ. Inducible tumor-specific...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন

প্রধান লেখক:	David Cunningham, Paul Ross, Ruth Plummer, Joshua Savage, Gary Middleton, Mark Saunders, Daniel Palmer, Anne Thomas, Lucinda Billingham, Sally Clive, Vicky Coyle, John Bridgewater, Phillipe Taniere, Charlotte Gaskell
বিন্যাস:	Artigo
ভাষা:	Inglês
প্রকাশিত:	BMJ Publishing Group 2025-12-01
মালা:	Journal for ImmunoTherapy of Cancer
অনলাইন ব্যবহার করুন:	https://jitc.bmj.com/content/13/12/e012749.full
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!